Comparison 6. Sensitivity analysis 2: full reports.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure to control bleeding	13	1551	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.07, 0.02]
1.1 EVS compared with vasopressin	1	64	Risk Difference (M‐H, Random, 95% CI)	‐0.23 [‐0.44, ‐0.03]
1.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.12, 0.09]
1.3 EVS compared with somatostatin	4	247	Risk Difference (M‐H, Random, 95% CI)	‐0.03 [‐0.11, 0.06]
1.4 EVS compared with octreotide	8	1021	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.07, 0.05]
2 Five‐day failure rate	8	879	Risk Difference (M‐H, Random, 95% CI)	‐0.03 [‐0.09, 0.02]
2.1 EVS compared with vasopressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.14, 0.11]
2.3 EVS compared with somatostatin	3	319	Risk Difference (M‐H, Random, 95% CI)	‐0.03 [‐0.11, 0.06]
2.4 EVS compared with octreotide	4	341	Risk Difference (M‐H, Random, 95% CI)	‐0.05 [‐0.14, 0.04]
3 Rebleeding	14	1663	Risk Difference (M‐H, Random, 95% CI)	0.02 [‐0.02, 0.06]
3.1 EVS compared with vasopressin	1	64	Risk Difference (M‐H, Random, 95% CI)	0.04 [‐0.17, 0.26]
3.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	0.01 [‐0.11, 0.12]
3.3 EVS compared with somatostatin	4	359	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.11, 0.07]
3.4 EVS compared with octreotide	8	1021	Risk Difference (M‐H, Random, 95% CI)	0.02 [‐0.04, 0.08]
4 Rebleeding before other elective treatments	9	1024	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.06, 0.03]
4.1 EVS compared with vasopressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	‐0.00 [‐0.09, 0.09]
4.3 EVS compared with somatostatin	3	319	Risk Difference (M‐H, Random, 95% CI)	‐0.03 [‐0.11, 0.05]
4.4 EVS compared with octreotide	5	486	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.07, 0.05]
5 Mortality	14	1663	Risk Difference (M‐H, Random, 95% CI)	‐0.03 [‐0.07, 0.02]
5.1 EVS compared with vasopressin	1	64	Risk Difference (M‐H, Random, 95% CI)	‐0.11 [‐0.34, 0.11]
5.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	‐0.08 [‐0.19, 0.03]
5.3 EVS compared with somatostatin	4	359	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.10, 0.06]
5.4 EVS compared with octreotide	8	1021	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.08, 0.04]
6 Mortality before other elective treatments	7	681	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.05, 0.03]
6.1 EVS compared with vasopressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
6.2 EVS compared with terlipressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
6.3 EVS compared with somatostatin	2	150	Risk Difference (M‐H, Random, 95% CI)	‐0.03 [‐0.13, 0.07]
6.4 EVS compared with octreotide	5	531	Risk Difference (M‐H, Random, 95% CI)	‐0.00 [‐0.05, 0.04]
7 Transfusions	7	806	Mean Difference (IV, Random, 95% CI)	‐0.35 [‐0.56, ‐0.13]
7.1 EVS compared with vasopressin	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
7.2 EVS compared with terlipressin	1	219	Mean Difference (IV, Random, 95% CI)	0.20 [‐1.01, 1.41]
7.3 EVS compared with somatostatin	2	239	Mean Difference (IV, Random, 95% CI)	0.48 [‐1.79, 2.75]
7.4 EVS compared with octreotide	4	348	Mean Difference (IV, Random, 95% CI)	‐0.32 [‐0.75, 0.11]
8 Adverse events	9	1024	Risk Difference (M‐H, Random, 95% CI)	0.11 [0.04, 0.17]
8.1 EVS compared with vasopressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
8.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	0.10 [‐0.02, 0.21]
8.3 EVS compared with somatostatin	3	319	Risk Difference (M‐H, Random, 95% CI)	0.18 [0.10, 0.26]
8.4 EVS compared with octreotide	5	486	Risk Difference (M‐H, Random, 95% CI)	0.07 [‐0.04, 0.18]
9 Serious adverse events	4	538	Risk Difference (M‐H, Random, 95% CI)	0.05 [0.01, 0.09]
9.1 EVS compared with vasopressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
9.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	0.03 [‐0.03, 0.09]
9.3 EVS compared with somatostatin	3	319	Risk Difference (M‐H, Random, 95% CI)	0.07 [0.01, 0.13]
9.4 EVS compared with octreotide	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]